{"id":1454,"date":"2010-03-04T19:10:26","date_gmt":"2010-03-05T00:10:26","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/thursday-march-4-news-apixaban-advances\/"},"modified":"2011-07-19T17:45:01","modified_gmt":"2011-07-19T21:45:01","slug":"thursday-march-4-news-apixaban-advances","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/03\/04\/thursday-march-4-news-apixaban-advances\/","title":{"rendered":"Thursday, March 4 News: Apixaban Advances"},"content":{"rendered":"<p>Apixaban, a new factor Xa inhibitor under development, was compared&nbsp;with enoxaparin for thromboprophylaxis following knee replacement surgery in the ADVANCE-2 trial. The new report appears in the <em><\/em><a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2809%2962125-5\/fulltext\"><em>Lancet<\/em><\/a>. In the primary efficacy analysis, the primary outcome&nbsp;\u2014&nbsp;the composite of asymptomatic and symptomatic deep vein thrombosis, nonfatal pulmonary embolism, and all-cause death during treatment&nbsp;\u2014 was reached in&nbsp;15% of apixaban patients compared&nbsp;with 24% of enoxaparin patients, a highly significant difference. Major or other clinically relevant bleeding was reported in 4% of the apixaban group versus 5% of the enoxaparin group.&nbsp;<br \/>\n&nbsp;&nbsp;&nbsp;&nbsp;In an <a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2810%2960139-0\/fulltext\">accompanying comment, Jawed Fareed and Russell Hull<\/a> note that in the previously published&nbsp;<a href=\"http:\/\/content.nejm.org\/cgi\/content\/abstract\/361\/6\/594\">ADVANCE-1<\/a>&nbsp;trial, apixaban did not demonstrate noninferiority when compared to a different enoxaparin regimen,&nbsp;although it was associated with a lower bleeding rate. (ADVANCE-2 used the enoxaparin regimen most commonly employed outside the U.S.; ADVANCE-1 used the standard U.S. regimen.) The editorialists write&nbsp;that ADVANCE-2 brings us &#8220;potentially a step closer to the unmet need of oral antithrombotic therapy without need for monitoring.&#8221; Other new agents, including rivaroxaban and dabigatran, may also fill this need, they say.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apixaban, a new factor Xa inhibitor under development, was compared&nbsp;with enoxaparin for thromboprophylaxis following knee replacement surgery in the ADVANCE-2 trial. The new report appears in the Lancet. In the primary efficacy analysis, the primary outcome&nbsp;\u2014&nbsp;the composite of asymptomatic and symptomatic deep vein thrombosis, nonfatal pulmonary embolism, and all-cause death during treatment&nbsp;\u2014 was reached in&nbsp;15% [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1454","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1454"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1454\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}